The stock may react negatively to declining revenue despite improved margins and cost controls. Watch whether 2026 guidance is achievable given Q1 2026 expected revenue of $6.5–$6.7M (down from Q4 2025's $7.95M). Cash runway and execution on commercial adoption will be critical given the company's small market cap of $12M.
Price Chart
Executive Summary
Bionano Genomics reported Q4 and full-year 2025 results with declining revenue and net losses, though gross margins and operating expenses improved significantly year-over-year. Total revenue fell 7% to $28.5 million for the year, driven by lower instrument and service revenue, but consumables and software grew 7%. The company initiated 2026 revenue guidance of $30–$33 million, signaling expected recovery.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $28.5 million, down 7% YoY from $30.8 million
- Q4 2025 revenue was $7.95 million, down 3% YoY from $8.16 million
- Net loss for 2025 was $26.4 million, a significant improvement from $112.0 million in 2024
- Gross margin improved to 46% in 2025 from 1% in 2024 due to cost restructuring and inventory impairment in prior year
- Operating expenses slashed by 55% to $46.5 million in 2025 from $104.4 million in 2024
- Company guided 2026 revenue to $30–$33 million, above 2025 levels
- Cash and equivalents totaled $29.6 million at year-end, down from $9.17 million in cash and $302k in investments in 2024
Financial Impact
Revenue declined 7% YoY to $28.5M, but cost discipline drove gross margin expansion from 1% to 46%. Operating expenses cut by $57.8M. 2026 guidance implies 5-16% revenue growth.
Risk Factors
- Revenue has declined for two consecutive years; 2026 growth guidance must be achieved to restore confidence
- Net loss remains substantial at $26.4M despite cost cuts, raising sustainability concerns
- High reliance on future adoption of OGM and reimbursement via CPT code expansion
- Company previously disclosed going concern risk; cash of $29.6M may not be sufficient without additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260830 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $1.22 $1.16 | ▼ −4.92% | ▼ −4.77% | $1.19 (−2.46%) |
Sep 14, 2026 6w ago | Press Release | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.19 (−10.53%) |
Sep 14, 2026 6w ago | 8-K | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.19 (−10.53%) |
Aug 10, 2026 11w ago | 8-K | $1.19 $1.18 | ▼ −0.84% | ▼ −0.44% | $1.19 (+0.00%) |
Jun 5, 2026 20w ago | 8-K | $1.17 $1.16 | ▲ +0.85% | ▲ +2.97% | $1.19 (−1.71%) |
May 28, 2026 21w ago | 8-K | $1.25 $1.30 | ▲ +4.00% | ▲ +4.05% | $1.19 (−4.80%) |
Mar 23, 2026 31w ago | Press Release | $1.18 $1.17 | ▲ +0.85% | ▲ +0.42% | $1.19 (−0.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers